These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30447530)

  • 1. Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency.
    Tortorici MA; Lawo JP; Weide R; Jochems J; Puli S; Hofmann J; Pfruender D; Rojavin MA
    Int Immunopharmacol; 2019 Jan; 66():119-126. PubMed ID: 30447530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
    Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
    Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 10% liquid immunoglobulin preparation for intravenous use (Privigen®) in paediatric patients with primary immunodeficiencies and hypersensitivity to IVIG.
    Lozano-Blasco J; Martín-Mateos MA; Alsina L; Domínguez O; Giner MT; Piquer M; Alvaro M; Plaza AM
    Allergol Immunopathol (Madr); 2014; 42(2):136-41. PubMed ID: 23253680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacometric Analysis of IgPro10 in Japanese and Non-Japanese Patients With Primary Immunodeficiency.
    Luo D; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
    Clin Ther; 2020 Jan; 42(1):196-209.e5. PubMed ID: 31910997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases.
    Dumas T; Berry NS; Wolfsegger M; Jolles S; McCoy B; Yel L
    Int Immunopharmacol; 2019 Jun; 71():404-410. PubMed ID: 30952104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multi-centre study of efficacy and safety of Intratect®, a novel intravenous immunoglobulin preparation.
    Kreuz W; Erdös M; Rossi P; Bernatowska E; Espanol T; Maródi L
    Clin Exp Immunol; 2010 Sep; 161(3):512-7. PubMed ID: 20550545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with an L-proline–stabilized 10 %intravenous immunoglobulin (Privigen®): real-life effectiveness and tolerability.
    Dorsey MJ; Ho V; Mabudian M; Soler-Palacín P; Domínguez-Pinilla N; Rishi R; Rishi R; Wong D; Rojavin M; Hubsch A; Berger M
    J Clin Immunol; 2014 Oct; 34(7):804-12. PubMed ID: 24981039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex
    Wasserman RL; Melamed IR; Stein MR; Jolles S; Norton M; Moy JN;
    J Clin Immunol; 2017 Apr; 37(3):301-310. PubMed ID: 28316003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of Privigen
    Morio T; Baheti G; Tortorici MA; Hofmann J; Rojavin MA
    Immunol Med; 2019 Dec; 42(4):162-168. PubMed ID: 31847720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
    Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
    Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency.
    Rojavin MA; Hubsch A; Lawo JP
    J Clin Immunol; 2016 Apr; 36(3):210-9. PubMed ID: 26910102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flebogamma(®) 5 % DIF Intravenous Immunoglobulin for Replacement Therapy in Children with Primary Immunodeficiency Diseases.
    Ballow M; Pinciaro PJ; Craig T; Kleiner G; Moy J; Ochs HD; Sleasman J; Smits W
    J Clin Immunol; 2016 Aug; 36(6):583-9. PubMed ID: 27279130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
    Berger M; Rojavin M; Kiessling P; Zenker O
    Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.
    van der Meer JW; van Beem RT; Robak T; Deptala A; Strengers PF
    Vox Sang; 2011 Aug; 101(2):138-46. PubMed ID: 21749402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
    Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
    Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adequate IVIG dosing is associated with an improved long-term outcome in secondary immunodeficiency: A prospective, non-interventional study.
    Bauhofer A; Balaban Ü; Schimo S; Mayer M; Schüttrumpf J; Borte S
    Int J Clin Pharmacol Ther; 2024 Oct; 62(10):448-459. PubMed ID: 39078054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis comparing hospital-based intravenous immunoglobulin with home-based subcutaneous immunoglobulin in patients with secondary immunodeficiency.
    Windegger TM; Nghiem S; Nguyen KH; Fung YL; Scuffham PA
    Vox Sang; 2019 Apr; 114(3):237-246. PubMed ID: 30883804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A; Bauer M; Kremer S
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.